Evidence map›Paper›PMID 35884598›Full record

ArticleCancers2022

Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma.

Wei Ouyang, Lufeng Luo, Junjie Zhang, Ran Xu, Qiang Lu, Zhenzhou Xu, Jianye Liu, Pei Li, Yaqun Zhang, Chuanchi Zhou and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Review
  8. Article
  9. Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Wei OuyangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0001-9512-0010
Lufeng LuoDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.
Junjie ZhangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.
Ran XuDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha 410028, China.
Qiang LuDepartment of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha 410002, China.
Zhenzhou XuDepartment of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medical, Central South University, Changsha 410013, China.
Jianye LiuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.
Pei LiYearth Biotechnology Co., Ltd., Changsha 410205, China.
Yaqun ZhangDepartment of Urology, Beijing Hospital, Beijing 100000, China.
Chuanchi ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.
Wei TangYearth Biotechnology Co., Ltd., Changsha 410205, China.
Zhenting WangAffiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou 570100, China.
Manman CaoYearth Biotechnology Co., Ltd., Changsha 410205, China.
Genming XuYearth Biotechnology Co., Ltd., Changsha 410205, China.
Long WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0003-4583-2428
Central South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHunan Normal University · CN

Funding

Bethune Special Research Fund Project of Urological Oncology mnzl202006Hunan High-tech Industry Science and Technology Innovation Leading Plan 2020SK2012the Key R&D projects of Changsha City, Hunan Province kh1902017
6 · The paper itself

Abstract

backgroundTo improve the selection of patients for ureteroscopy, avoid excessive testing and reduce costs, we aimed to develop and validate a diagnostic urine assay for upper tract urinary carcinoma (UTUC).

methodsIn this cohort study we recruited 402 patients from six Hunan hospitals who underwent ureteroscopy for hematuria, including 95 patients with UTUC and 307 patients with non-UTUC findings. Midstream morning urine samples were collected before ureteroscopy and surgery. DNA was extracted and qPCR was used to analyze mutations in

resultsThe panel combining the methylation with mutation markers led to an AUC of 0.958 (95% CI: 0.933-0.975) with a sensitivity of 91.58% and a specificity of 94.79%. The panel presented a favorable diagnostic value for UTUC vs. other malignant tumors (AUC = 0.920) and UTUC vs. benign disease (AUC = 0.975). Furthermore, combining the panel with age revealed satisfactory results, with 93.68% sensitivity, 94.44% specificity, AUC = 0.970 and NPV = 98.6%. In the external validation process, the model showed an AUC of 0.971, a sensitivity of 95.83% and a specificity of 92.31, respectively.

conclusionsA novel diagnostic model for analyzing hematuria patients for the risk of UTUC was developed, which could lead to a reduction in the need for invasive examinations. Combining

Indexed as

DNA methylationgene mutationliquid biopsyupper tract urinary carcinoma

Identifiers

PMID35884598
PMCPMC9319988
OpenAlexW4286491673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.